A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Participants With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

A Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Ocrelizumab in Chinese Patients With Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

The main purpose of this study is to evaluate the efficacy of ocrelizumab in participants with relapsing multiple sclerosis (RMS) and to characterize the ocrelizumab pharmacodynamic (PD) profile in Chinese participants with primary progressive multiple sclerosis (PPMS).

Study Overview

• Status: Recruiting
• Conditions: Relapsing Multiple Sclerosis; Primary Progressive Multiple Sclerosis
• Intervention / Treatment: Drug: Ocrelizumab

• Study Type: Interventional
• Enrollment (Estimated): 60
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Reference Study ID Number: YN44938 https://forpatients.roche.com/; Phone Number: 888-662-6728; Email: global-roche-genentech-trials@gene.com

Study Locations

• China
  • Beijing, China, 100034
    • Recruiting
    • Peking University First Hospital
  • Beijing, China, 100032
    • Recruiting
    • Peking Union Medical College Hospital
  • Beijing, China, 100730
    • Recruiting
    • Beijing Hospital of Ministry of Health
  • Changsha, China, 410008
    • Recruiting
    • Xiangya Hospital Central South University
  • Chengdu, China, 610041
    • Recruiting
    • West China Hospital of Sichuan University
  • Chongqing, China, 400016
    • Recruiting
    • The First Affiliated Hospital, Chongqing Medical University
  • Guangzhou, China, 510630
    • Recruiting
    • The Third Affiliated Hospital Of Sun Yat-Sen University
  • Guangzhou, China, 510080
    • Recruiting
    • The First Affiliated Hospital of Sun Yat-sen University
  • Hangzhou, China, 310003
    • Recruiting
    • The First Affiliated Hospital of College of Medicine, Zhejiang University
  • Hohhot, China, 010011
    • Recruiting
    • Inner Mongolia Autonomous Region People's Hospital
  • Lanzhou, China, 730030
    • Recruiting
    • Lanzhou university second hospital
  • Shenyang, China, DUMMY_VALUE
    • Recruiting
    • The First Hospital of China Medical University
  • Shijiazhuang, China, 050000
    • Active, not recruiting
    • The Second Hospital of Hebei Medical University
  • Taiyuan, China, 030000
    • Recruiting
    • 1st Affiliated Hospital of Shanxi Medical University
  • Wuhan, China, 430030
    • Recruiting
    • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology
  • Ürümqi, China, 830000
    • Recruiting
    • Xinjiang People Hospital
  • Jiangxi
    • Nanchang, Jiangxi, China, 330209
      • Recruiting
      • The First Affiliated Hospital of Nanchang University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosis of RMS/PPMS in accordance with the revised 2017 McDonald Criteria
• EDSS score from 0-5.5 (RMS) or 3.0-6.5 (PPMS), inclusive, at screening and baseline
• Documented MRI of brain with abnormalities consistent with MS before screening

Exclusion Criteria:

• Diagnosis of PPMS or non-active secondary progressive multiple sclerosis (SPMS) (only for RMS cohort)
• History of relapsing remitting multiple sclerosis (RRMS) or SPMS at screening (only for PPMS cohort)
• Disease duration of more than 10 years in participants with an EDSS ≤ 2.0 at screening (only for RMS cohort)
• History of confirmed or suspected progressive multifocal leukoencephalopathy (PML)
• Inability to complete an MRI scan or contraindication to Gd administration
• Contraindications to mandatory pre-medications (i.e., corticosteroids and antihistamines)
• Known presence of other neurologic disorders if they could interfere with the diagnosis of MS or assessments of efficacy and/or safety during the study
• Any concomitant disease that may require chronic treatment with systemic corticosteroids or immunosuppressants during the course of the study
• Known history of human immunodeficiency virus (HIV) infection
• Lack of peripheral venous access
• Previous treatment with B-cell targeted therapies (i.e., rituximab, ocrelizumab, atacicept, belimumab, or ofatumumab), unless the last infusion was at least 6 months prior to screening
• Positive screening tests for hepatitis B virus (HBV) and/or hepatitis C virus (HCV)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: RMS Cohort; Participants with RMS will receive ocrelizumab, 300 milligrams (mg), intravenous (IV) infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, for all subsequent cycles every 24 weeks (Q24W) (1 Cycle=24 weeks).	Drug: Ocrelizumab; Ocrelizumab will be administered as per the schedule specified in the respective arms.; Other Names: RO4964913; OCREVUS®
Experimental: PPMS Cohort; Participants with PPMS will receive ocrelizumab, 300 mg, IV infusions on Days 1 and 15 of Cycle 1 and thereafter as a single infusion of 600 mg, IV, at Week 24 (1 Cycle=24 weeks).	Drug: Ocrelizumab; Ocrelizumab will be administered as per the schedule specified in the respective arms.; Other Names: RO4964913; OCREVUS®

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
RMS Cohort: Annualized Protocol-defined Relapse Rate	Up to approximately 1.6 years
PPMS Cohort: B-cell Levels in Blood	Up to Week 48
PPMS Cohort: Percentage of Participants Achieving Cluster of Differentiation 19 (CD19+) B-cell Levels of <10 Cells/Microliter (μL) at Week 48	At Week 48

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
RMS Cohort: Percentage of Participants Who Have No Evidence of Disease Activity (NEDA3) During a 48-week Period		Up to Week 48
RMS Cohort: Percentage of Relapse-free Participants by Week 48		Up to Week 48
RMS Cohort: Percentage of Participants Who Have NEDA3 During a 24-week Period		Up to Week 24
RMS Cohort: Total Number of T1 Gadolinium (Gd)-enhancing Lesions as Detected by Brain Magnetic Resonance Imaging (MRI)		Up to Week 48
RMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI		Up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in the Concentration of Serum Neurofilament Light Chain (Nfl)		Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Expanded Disability Status Scale (EDSS)	EDSS is a scale for assessing neurologic impairment in participants with multiple sclerosis (MS). EDSS is based on a standard neurological examination, incorporating functional systems (visual, brainstem, pyramidal, cerebellar, sensory, bowel and bladder, and cerebral [or mental]) that are rated and then scored as a functional systems scores (FSS), and ambulation, which is scored as ambulation score. Each FSS is an ordinal clinical rating scale ranging from 0 to 5 or 6 and an ambulation score that is rated from 0 to 16. These ratings are then used in conjunction with observations, as well as information, concerning ambulation and use of assistive devices to determine the total EDSS score. Values are from 0 points (normal neurological examination) up to 10 points (death), increasing in increments of 0.5 points. Higher scores represent increased disability.	Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in Timed 25-Foot Walk Test (T25FWT)	The T25FWT test is a performance measure used to assess walking speed based on a timed 25-foot walk. The participant is directed to start at one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly and safely as possible and immediately walk back the same distance. Score for the T25FWT is the average of the two completed trials. The time taken to complete the test is measured in seconds. The longer it takes to walk, higher the score, which indicates deterioration and greater impairment. Lower times indicate better performance and greater mobility. A 20% change from baseline of the averaged T25FWT is typically considered clinically meaningful.	Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline to Week 48 in 9-Hole Peg Test (9-HPT)	The 9-HPT is a performance measure used to assess upper extremity (arm and hand) function. Participants are instructed to place pegs one by one into each of nine holes arranged in a board stabilized with a plastic nonslip sheet on a solid table, and then to remove these pegs from the holes. Both the dominant and non-dominant hands are tested twice (two consecutive trials for each hand). The participants are required to complete two successful trials for each hand. The amount of time (in seconds) required to place and remove all nine pegs is recorded for each trial. More time indicates higher raw scores, which indicates deterioration. A 20% change from baseline is typically considered clinically meaningful.	Baseline up to Week 48
RMS and PPMS Cohorts: Change From Baseline in EuroQoL 5-Dimension Questionnaire (5-Level Version; EQ-5D-5L) Index Score at Week 48	The EQ-5D-5L is a self-reported health status questionnaire that consists of six questions used to calculate a health utility score for use in health economic analysis. There are two components to the EQ-5D-5L: a five-item health state profile that assesses mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a visual analogue scale (VAS) that measures health state. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state.	Baseline, Week 48
RMS and PPMS Cohorts: Serum Concentration of Ocrelizumab		Up to Week 48
RMS Cohort: B-cell Levels in Blood		Up to Week 48
RMS Cohort: Percentage of Participants Achieving CD19+ B-cell Levels of <10 cells/μL at Week 48		At Week 48
PPMS Cohort: Total Number of T1 Gd-enhancing Lesions as Detected by Brain MRI at Week 24 and Week 48		Week 24 and Week 48
PPMS Cohort: Total Number of New or Enlarging T2 Hyperintense Lesions as Detected by Brain MRI at Week 24 and Week 48		Week 24 and Week 48
RMS and PPMS Cohorts: Number of Participants With Adverse Events (AEs)		Up to approximately 1.8 years
RMS and PPMS Cohorts: Change from Baseline in T-cell Level		Up to approximately 1.8 years
RMS and PPMS Cohorts: Percentage of Participants With Suicidal Ideation or Behaviour, as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)	C-SSRS is an assessment tool used to assess lifetime suicidality of participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, and attempts with actual/potential lethality. Categories have binary responses (yes/no) and include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher indicate suicidal ideation or behavior.	Up to approximately 1.8 years

Collaborators and Investigators

• Sponsor: Hoffmann-La Roche
• Investigators: Study Director: Clinical Trials, Hoffmann-La Roche

Study record dates

Study Major Dates

• Study Start (Actual): July 4, 2025
• Primary Completion (Estimated): March 12, 2027
• Study Completion (Estimated): April 23, 2027

Study Registration Dates

• First Submitted: March 16, 2026
• First Submitted That Met QC Criteria: March 16, 2026
• First Posted (Actual): March 19, 2026

Study Record Updates

• Last Update Posted (Actual): May 27, 2026
• Last Update Submitted That Met QC Criteria: May 22, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Nervous System Diseases; Pathologic Processes; Chronic Disease; Disease Attributes; Autoimmune Diseases; Immune System Diseases; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Demyelinating Diseases; Pathological Conditions, Signs and Symptoms; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive; ocrelizumab
• Other Study ID Numbers: YN44938

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No